122 related articles for article (PubMed ID: 8344735)
1. Preclinical & pharmaceutical testing of liposomal amphotericin B.
Gokhale PC; Kotwani RN; Dange SY; Kshirsagar NA; Pandya SK
Indian J Med Res; 1993 Apr; 98():75-8. PubMed ID: 8344735
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
[TBL] [Abstract][Full Text] [Related]
4. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B.
Ahmad I; Sarkar AK; Bachhawat BK
Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
6. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis.
Ahmad I; Sarkar AK; Bachhawat BK
Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483
[No Abstract] [Full Text] [Related]
9. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
10. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin.
Moonis M; Ahmad I; Bachhawat BK
Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960
[TBL] [Abstract][Full Text] [Related]
11. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
Patterson TF; Andriole VT
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S63-8. PubMed ID: 2693111
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerance of liposomal amphotericin B in patients.
Gokhale PC; Barapatre RJ; Advani SH; Kshirsagar NA; Pandya SK
J Antimicrob Chemother; 1993 Jul; 32(1):133-9. PubMed ID: 8226404
[TBL] [Abstract][Full Text] [Related]
13. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
Zager RA
Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
Bellocchio S; Gaziano R; Bozza S; Rossi G; Montagnoli C; Perruccio K; Calvitti M; Pitzurra L; Romani L
J Antimicrob Chemother; 2005 Feb; 55(2):214-22. PubMed ID: 15649994
[TBL] [Abstract][Full Text] [Related]
15. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of amphotericin B(Fungizone) in rat brain total lipid liposomes markedly decreases its i.v. toxicity in mice.
Gergel D; Ondrias K
Pharmazie; 1993 Mar; 48(3):202-5. PubMed ID: 8388108
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
18. Liposomal polyene antibiotics.
Ng AW; Wasan KM; Lopez-Berestein G
Methods Enzymol; 2005; 391():304-13. PubMed ID: 15721388
[TBL] [Abstract][Full Text] [Related]
19. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
Chakraborty KK; Naik SR
Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
[TBL] [Abstract][Full Text] [Related]
20. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
